Cargando…
Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes
[Image: see text] Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically changed the treatment outcomes of different types of cancers. However, many patients still do not r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909687/ https://www.ncbi.nlm.nih.gov/pubmed/36777563 http://dx.doi.org/10.1021/acsomega.2c05986 |
_version_ | 1784884627485229056 |
---|---|
author | Nasser, Tasneem A. Adel, Rawan Badr, Abdelrahman Teleb, Mohamed Bekhit, Adnan A. Elkhodairy, Kadria A. Abdelhamid, Ahmed S. Elzoghby, Ahmed O. |
author_facet | Nasser, Tasneem A. Adel, Rawan Badr, Abdelrahman Teleb, Mohamed Bekhit, Adnan A. Elkhodairy, Kadria A. Abdelhamid, Ahmed S. Elzoghby, Ahmed O. |
author_sort | Nasser, Tasneem A. |
collection | PubMed |
description | [Image: see text] Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically changed the treatment outcomes of different types of cancers. However, many patients still do not respond to immunotherapies, and many also suffer from severe immune-related side effects. Recent advances in the fields of nanomedicine bioengineering and in particular imaging offered new approaches which can enhance not only the safety but also the efficacy of immunotherapy. Theranostics has showed great progress as a branch of medicine which integrates both diagnosis and therapy in a single system. The outcomes from animal studies demonstrated an improvement in the diagnostic and immunotherapeutic potential of nanoparticles within the theranostic framework. Herein, we discuss the most recent developments in the application of nanotheranostics for combining tumor imaging and cancer immunotherapies. |
format | Online Article Text |
id | pubmed-9909687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-99096872023-02-10 Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes Nasser, Tasneem A. Adel, Rawan Badr, Abdelrahman Teleb, Mohamed Bekhit, Adnan A. Elkhodairy, Kadria A. Abdelhamid, Ahmed S. Elzoghby, Ahmed O. ACS Omega [Image: see text] Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically changed the treatment outcomes of different types of cancers. However, many patients still do not respond to immunotherapies, and many also suffer from severe immune-related side effects. Recent advances in the fields of nanomedicine bioengineering and in particular imaging offered new approaches which can enhance not only the safety but also the efficacy of immunotherapy. Theranostics has showed great progress as a branch of medicine which integrates both diagnosis and therapy in a single system. The outcomes from animal studies demonstrated an improvement in the diagnostic and immunotherapeutic potential of nanoparticles within the theranostic framework. Herein, we discuss the most recent developments in the application of nanotheranostics for combining tumor imaging and cancer immunotherapies. American Chemical Society 2023-01-27 /pmc/articles/PMC9909687/ /pubmed/36777563 http://dx.doi.org/10.1021/acsomega.2c05986 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Nasser, Tasneem A. Adel, Rawan Badr, Abdelrahman Teleb, Mohamed Bekhit, Adnan A. Elkhodairy, Kadria A. Abdelhamid, Ahmed S. Elzoghby, Ahmed O. Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes |
title | Combined Cancer
Immunotheranostic Nanomedicines: Delivery
Technologies and Therapeutic Outcomes |
title_full | Combined Cancer
Immunotheranostic Nanomedicines: Delivery
Technologies and Therapeutic Outcomes |
title_fullStr | Combined Cancer
Immunotheranostic Nanomedicines: Delivery
Technologies and Therapeutic Outcomes |
title_full_unstemmed | Combined Cancer
Immunotheranostic Nanomedicines: Delivery
Technologies and Therapeutic Outcomes |
title_short | Combined Cancer
Immunotheranostic Nanomedicines: Delivery
Technologies and Therapeutic Outcomes |
title_sort | combined cancer
immunotheranostic nanomedicines: delivery
technologies and therapeutic outcomes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909687/ https://www.ncbi.nlm.nih.gov/pubmed/36777563 http://dx.doi.org/10.1021/acsomega.2c05986 |
work_keys_str_mv | AT nassertasneema combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT adelrawan combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT badrabdelrahman combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT telebmohamed combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT bekhitadnana combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT elkhodairykadriaa combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT abdelhamidahmeds combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes AT elzoghbyahmedo combinedcancerimmunotheranosticnanomedicinesdeliverytechnologiesandtherapeuticoutcomes |